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Synopsis
Easily accessible biomarkers are needed to diagnose cardiovascular disease precisely – particularly, to distinguish
between disease subtypes that are encountered in clinical practice. Per the hypothesis that plasma miRNA is valuable
for this purpose, we performed complete transcriptional profiling of an miRNA discovery-set in 14 samples: three
patients with ST-elevated acute myocardial infarction (STEMI) at baseline and after three months of follow-up, four
with stable ischaemic heart disease (stable-IHD) and four healthy age-matched volunteers. Our aim was to determine
whether we could distinguish patients with unstable plaques from stable patients following a STEMI event. After
analysing miRNA profiles, we conducted a validation study comparing three-month STEMI (n= 40) with stable-IHD
(n= 35), which confirmed that miR-486-3P differentiates patients with three-month STEMI from those with stable-IHD
(P= 0.019).
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INTRODUCTION
Troponin (cTn) measurements are commonly used by clinicians
to diagnose patients. cTn is generally accepted as the most reliable
biomarker for the diagnosis of acute coronary syndromes. Despite
its usefulness in the acute setting, cTn cannot distinguish between
patients with stable coronary artery disease and patients at risk for
coronary atherothrombosis in the general population [1]. Because
treatment and prognosis differ significantly in these populations
with coronary artery disease, it would be of interest to have
a biomarker which could potentially separate patients at risk
for atherothrombosis from patients with stable coronary artery
disease.
In an attempt to further develop diagnosis and risk-
stratification in patients with coronary artery disease, several
novel biomarkers have been examined, typically in combina-
tion with cTn [1]. One notable class of biomarkers is miRNAs,
which are approximately 22 nt noncoding RNAs that regulate
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gene expression at the post-transcriptional level. In the human
genome, miRNAs constitute 1 %–5 % of all genes, making them
the most abundant class of regulators. Although the function
of most miRNAs is unknown, they have been shown to me-
diate various pathological conditions, including cardiovascular
disease, and the levels of several miRNAs are altered in the heart
in response to pathological stress.
miRNAs have properties that render them attractive biomark-
ers. They are remarkably stable in blood and can be specifically
measured easily, which is typical of nucleotide-based markers
[2]. These features have led to many miRNA biomarker candid-
ates being reported [3], as reviewed in [4]. miRNA markers that
have continued on to validation studies have garnered significant
interest, such as miR-499, which has been shown to be an effect-
ive biomarker of acute myocardial infarction (AMI) in a Chinese
population [5].
In our study, we aimed to identify miRNA markers that could
distinguish patients stabilized following an acute coronary syn-
drome from patients with stable coronary artery disease. To this
c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
Licence 4.0 (CC BY).
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Table 1 Demographics of patients, stratified by cohort
Demographics of patients, stratified by cohort. Categorical variables are reported as percentage (count). Numerical variables are reported as
mean +− S.D. The STEMI-3 discovery group was assumed to have unchanged variables for all values except statin treatment, cholesterol and
triacylglycerols, for which no information was available. P-values for the validation cohort were calculated by Student’s t test for numerical variables
and chi-square test for categorical variables.
Discovery cohort Validation cohort
STEMI-0 STEMI-3 PCI Healthy STEMI-3 PCI P-value
n 3 3 4 4 40 35 0.66
Male gender 100 % (3) 100 % (3) 100 % (4) 100 % (4) 76 % (25) 84 % (21) 0.059
Age (years) 48 +− 3.6 48 +− 3.6 52 +− 3.6 52 +− 2.6 52 +− 6.9 55 +− 3.9 0.22
Cholesterol (mM) 6.6 +− 0.42 – 4.1 +− 1.5 5.6 +− 0.69 5.2 +− 1 4.8 +− 1.1 0.67
Triacylglycerols (mM) 2.8 +− 1.4 – 1.1 +− 0.46 1.3 +− 0.49 1.9 +− 1.3 2 +− 1.4 0.03
Smoker 0 % (0) 0 % (0) 0 % (0) 0 % (0) 52 % (17) 20 % (5) 1.80×10− 6
Statins 33 % (1) – 75 % (3) 0 % (0) 21 % (7) 88 % (22) 0.00035
β -Blockers 100 % (3) 100 % (3) 75 % (3) 0 % (0) 33 % (11) 84 % (21) 0.89
Waran 0 % (0) 0 % (0) 0 % (0) 0 % (0) 0 % (0) 0 % (0) 0.66
end, we measured the global expression of circulating miRNAs
and assessed their diagnostic value as sensitive biomarkers of
plaque stability in patients during the onset of and recovery
from STEMI, i.e. atherothrombosis, patients who were under-
going elective percutaneous coronary intervention (PCI), i.e.
stable ischaemic heart disease (stable-IHD), and healthy indi-
viduals. We focused primarily on patients at baseline and at
three-month follow-up after ST-elevated acute myocardial infarc-
tion (STEMI), as this time point reflects a time where the acute
atherothrombosis, myocardial injury and inflammatory response
has passed but where the risk of renewed atherothrombotic events
are elevated compared with patients with stable coronary artery
disease. If, in the future, miRNAs demonstrate the ability to fur-
ther risk-stratify and provide prognostic information they may
become important clinical instruments.
MATERIALS AND METHODS
Patient populations
For the global circulating miRNA array, we recruited three
STEMI patients 24 h–48 h after admission to the hospital
(STEMI-0) and three months after discharge (STEMI-3). Four
patients with stable coronary artery disease undergoing elective
PCI (stable-IHD) and four healthy individuals were added as con-
trols. For validation, a new cohort of 40 patients at three months
after hospital discharge (STEMI-3) and 35 patients undergoing
elective PCI (stable-IHD) were included (Table 1). All patients
provided written informed consent. The study was approved by
the Stockholm Regional Ethics Committee and conducted per the
Declaration of Helsinki.
Plasma sampling and RNA isolation
Blood samples were collected in ethylenediaminetetraacetic acid
(EDTA)-K2 tubes and processed by two-step centrifugation (4 ◦C
at 820 × g for 10 min and 4 ◦C at 16000 × g for 10 min). The
supernatant was then transferred to RNase/Dnase-free tubes and
stored at − 80 ◦C.
Total RNA was extracted from plasma using the CIAzol
miRNeasy kit (Qiagen) with some modifications. Briefly, 200 μl
of plasma was thawed on ice and lysed in 1 ml QIAzol lysis re-
agent. Samples in QIAzol were incubated at room temperature
for 5 min to promote dissociation of nucleoprotein complexes. To
adjust for variations in RNA extraction and co-purification of in-
hibitors, 5 μl of 5 nM synthetic Caenorhabditis elegans miRNAs,
cel-miR-39 miScript miRNA Mimic (Qiagen), was added to each
sample. The remainder of the extraction was performed as per
the manufacturer’s instructions. Each sample was eluted in 20 μl
RNase-free water and stored at − 70 ◦C.
Low-density miRNA array
miRNAs were reverse-transcribed using the TaqMan® miRNA
reverse-transcription kit with TaqMan miRNA Multiplex real
time assays (human pool; Applied Biosystems). The real time
PCR products were preamplified using the TaqMan PreAmp kit
(Applied Biosystems), the products of which were diluted in
0.1X TE (Tris/EDTA) buffer and subsequently used as a tem-
plate for miRNA expression profiling on TaqMan MicroRNA
Low-Density Arrays (TLDAs) (Applied Biosystems).
For the initial screen, Human TaqMan miRNA microarrays
(Card Av2.1 and Card Bv2.1, Applied Biosystems), covering
758 small, noncoding RNAs, were run on an ABI7900 HT with
the TLDA upgrade. Raw data were analysed with SDS Relative
Quantification, version 2.4.1, provided by Applied Biosystems.
All measurements with Ct values > 35 or with a flag for issues
according to the software were omitted (leaving 248, as plotted
in Supplementary Figure S2). This threshold and quality filtering
on low expression (Ct values > 35) left 201 miRNAs. Finally,
miRNAs where only one sample in a group had a measurement
passing quality control were omitted, leaving a final of 167758
miRNAs available for analysis.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2 c© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
Licence 4.0 (CC BY).
MicroRNA 486-3P and acute coronary syndrome
Figure 1 Expression profiles of miRNAs
LDA-generated expression profiles of the three miRNAs chosen for further validation.
For Ct normalization, the Ct of cel-miR-39 was subtracted
from that of the target, which was subtracted from the median
of the calibrator (healthy individuals) and linearized to obtain
2∧−Ct values [6]. For the alternative Ct normalization,
the same procedure was followed, except for the subtraction of
cel-miR-39. Plots of normalization values are shown in Supple-
mentary Figure S1.
Real-time PCR validation
Specific miRNAs by TaqMan® Real-Time PCR were quantified
as per the manufacturer (Applied Biosystems). Target gene ex-
pression was normalized as described above for the low-density
arrays (LDAs).
Statistics
All P-values were calculated by two-sided Student’s t test, assum-
ing non-equal variance. In the validation step, outlier measure-
ments outside of the 90 % confidence interval were omitted from
analysis to ensure normal distribution of the data. The validation
measurements were distributed normally by Shapiro–Wilk test
(P > 0.05). P-values were uncorrected for multiple testing. The
multiple testing burden of the discovery cohort was 201 tests, but
independent samples were used in the validation cohort to avoid
false discovery issues.
For testing of covariates, the following commonly used
measures were investigated: sex, age, cholesterol, triacylglycer-
ols, smoking, leucocytes, eosinophils, neutrophils, drug-eluting
stents (DES), erythrocyte volume fraction, haemoglobin, throm-
bocytes, monocytes, statins, β-blockers, waran, diuretics, non-
steroidal anti-inflammatory drug (NSAID), acetylsalicylic acid
(ASA), systolic blood pressure, diastolic blood pressure, pulse,
prior heart infarction, prior angina, ejection fraction, weight,
hip circumference, height and infection status. The associ-
ation between miR-486-3P and validation sample group was re-
calculated using each of these as a covariate in a linear regression
model according the formula: miRNA ∼ group + covariate.
The linear regression model was used as implemented in the lm
function in R version 3.2.3.
RESULTS
miRNA profiles in serum of patients and healthy
volunteers
Complete miRNA profiling was performed in 14 serum samples
from patients with STEMI at baseline (STEMI-0) and after
three months of follow-up (STEMI-3), patients with stable-IHD
and healthy age-matched volunteers. A total of 758 miRNAs
were measured on a LDA platform. After a filtration step for
poor quality and low expression, 167 miRNAs remained for
analysis.
Three normalization methods were tested before the miRNA
profiles were analysed: (1) a housekeeping gene method, using
the Ct method with U6 snRNA as an endogenous control; (2)
a spike-in method, using the Ct method with measured values
of cel-miR-39, which was spiked in before RNA purification; and
(3) an miRNA mass method, using a ‘Ct’ method in which a
comparable amount of total miRNA was assumed to exist in each
measurement. The relative Ct values of each normalization factor
are included as Supplementary Figure S1. Because the spike-in
method with cel-miR-39 demonstrated the least variation, it was
chosen for further analysis.
Discovery of differentially expressed miRNAs
For each measurable miRNA, we generated plots of their ex-
pression level as a function of patient group (Supplementary
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Figure S2). We aimed to identify biomarkers of plaque sta-
bility after acute myocardial infarction (MI), comparing global
miRNA expression between STEMI-3 and stable-IHD patients.
The plaque status of STEMI-3 patients was considered unstable.
All 167 miRNA expression profiles were inspected manually,
with a focus on strong differential expression between groups
(S2). Extra weight was given to miRNA profiles with comparable
expression between healthy individuals and stable-IHD patients.
Based on this analysis, miR-128a, miR-148a and miR-486-
3P (Figure 1) differentiated between patient groups. The levels
of these species in STEMI-3 differed from the stable-IHD and
healthy groups at magnitudes that had a realistic chance of be-
ing reproduced in a validation experiment. Unfortunately, the
recently validated baseline AMI biomarker miR-499 [5] had to
be omitted for quality control reasons and thus was not tested in
this cohort.
Validation of differentially expressed miRNA
Expression profiles were validated in the serum of 40 STEMI-3
patients and 35 patients from the stable-IHD group. miR-486-3P
was significantly validated, with 1.31-fold higher expression in
STEMI-3 compared with stable-IHD patients (P = 0.019, Fig-
ure 2A). Further, miR-148a and miR-128a were not significant:
P = 0.085 and P = 0.288 respectively, which excluded both from
further analysis.
Based on the validation of miR-486-3P in an independent co-
hort, we estimated its predictive ability using receiver operating
characteristic (ROC) curves. Based on the resulting thresholds,
miR-486-3P correctly predicted the unstable type (STEMI-3)
with 87 % probability and was incorrect for 60 % of patients
with stable disease (stable-IHD) (Figure 2B).
In the validation cohort, we examined whether the differen-
tial expression of miR-486-3P was attributed to common con-
founders, such as age, gender, smoking, statins, low density lipo-
protein (LDL) levels, triacylglycerol levels, cell counts, blood
pressure, presence of DES and 20 other frequently measured
clinical variables. The association between miR-486-3P and
sample group remained significant after inclusion of each co-
variate (P < 0.05), except for smoking which had a slight dimin-
ishing effect on the association of miR-486-3P and sample group
(P = 0.085).Thus, we conclude that the predictive value of miR-
486-3P was largely independent of routine confounders, although
smoking could be considered as a covariate of interest in future
studies.
DISCUSSION
The objective of our study was to identify miRNA-based bio-
markers that could distinguish patients stabilized following an
acute coronary syndrome from patients with stable coronary
artery disease, such as patients who are undergoing elective PCI.
Biomarkers which have larger variation in concentration levels
Figure 2 Biomarker validation data
(A) Validation measurements in an independent cohort of STEMI-3
(n= 40) and stable-IHD patients (n= 35), in which miR-486-3P is sig-
nificantly higher and at three months after an AMI event (P= 0.0192).
The y-axis shows 2∧−Ct values. (B) ROC curve of the predictive
ability of miR-486-3P to distinguish STEMI-3 and stable-IHD patients.
between patient groups than within patient groups are suitable
for this. We were prompted by our interest in allocating clin-
ical resources toward patients with the highest risk of future ad-
verse events. The detection of subtle, undetected STEMI would
benefit this prioritization, constituting a patent, unmet medical
need.
To this end, we developed a study on a discovery cohort,
comprising array-based miRNA-wide profiling, followed by ex-
amination of a validation cohort by follow-up measurements of
specific miRNAs. This design best balanced the cost of the ex-
pensive array-based method with the need for a sufficient sample
size to overcome the burden of multiple testing.
From the discovery cohort, we selected three miRNAs that had
a desirable profile with regard to our primary aim. These miRNAs
were measured in a larger independent cohort, from whom the
main finding of the present study was derived – that miR-486-3p
reproducibly distinguishes patients three months after a STEMI
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from patients with stable coronary artery disease patients. Also,
the effect was independent of other commonly measured clinical
parameters. These properties, in addition to serum miRNA being
stable and easy to measure, render miR-486-3p a potential marker
for use in precision medicine. Notably, Hsu et al. [7] reported
that miR-486-3p is differentially expressed between STEMI pa-
tients at baseline and healthy controls, further underscoring that
miR-486-3P might have clinical value in STEMI. In line with
Hsu et al. [7], we can also detect elevated plasma miR-
486-3P at STEMI-0 compared with healthy controls (Fig-
ure 1). The injured myocardium could be a source for miR-
486-3P. However, miR-486-3P is still detectable three months
after suggesting that miR-486-3P has other origins outside the
myocardium.
Although the predictive ability of miR-486-3P is at best mod-
est, there are few predictive methods for late STEMI, and any
ability to focus limited clinical resources might benefit a patient’s
quality of care. Similarly, much work is being performed to create
multi-signature prediction profiles, and a novel biomarker from a
nonstandard class has the potential to contribute additional clin-
ical knowledge. Thus, our findings can effect more precise and
data-driven clinical management.
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